DMAC vs JBIO

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Jun 25, 2026

DMAC

57.4
AI Score
VS
DMAC Wins

JBIO

53.4
AI Score

Investment Advisor Scores

DMAC

57score
Recommendation
HOLD

JBIO

53score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric DMAC JBIO Winner
Net Income -10.04M -40.37M DMAC
Operating Income -10.48M -43.45M DMAC
ROE -21.3% -13.6% JBIO
ROA -18.9% -12.6% JBIO
Total Assets 53.08M 319.43M JBIO
Cash 4.87M 55.09M JBIO
Current Ratio 9.11 14.29 JBIO
Free Cash Flow -9.09M -24.28M DMAC

Relative Price Performance (Last 90 Days)

DMAC 1M: -18.5% · 3M: +7.9% JBIO 1M: -5.1% · 3M: -17.6%

Current Technical Phase

DMAC

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 44

RSI (14): 44.3 · Price: $6.53

JBIO

Distribution
Trim / tighten stop

Price near a flattening SMA50 (slope -7.3%) with fading momentum, RSI 50

RSI (14): 49.6 · Price: $20.21

Fundamentals Snapshot

Metric DMAC JBIO
Market Cap
Forward P/E -7.4 -8.7
Trailing P/E
Revenue (TTM)
Revenue Growth 0.0% 0.0%
Gross Margin
Operating Margin 0.0% 0.0%
EPS -0.71 -2.72
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, DMAC is currently the stronger investment candidate, winning 3 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.